[exclusive] China Pharmaceutical Park Series: Zhangjiang High Tech & China class 1 new drug incubation base

Zhangjiang High Tech pharmaceutical Park, 1 / 3 of the "class 1 new drugs" in China originated here The success rate of new drug application is three times of the national level It brings together the top medical scientists in the country to promote the successful listing of one young pharmaceutical enterprise after another If every new drug R & D worker has a dream of Zhangjiang, it is better to say that Zhangjiang is making the dream of those who have ideas come true 1 Brief introduction of Zhangjiang hi tech park, known as China's Silicon Valley; founded in July 1992, located in the south central part of Pudong New Area in Shanghai, Zhangjiang hi tech park is a national high-tech park in China Together with Lujiazui, Jinqiao and Waigaoqiao development zones, Zhangjiang hi tech park is one of the four key development zones in Pudong New Area in Shanghai Shanghai Zhangjiang High Tech Park Development Co., Ltd was officially listed on the Shanghai Stock Exchange in April 1996 It is a joint-stock listed company established by public offering Company abbreviation: Zhangjiang High Tech, stock code: 600895 Zhangjiang hi tech is taking the technology investment bank as the strategic development direction, striving to build a new industrial real estate operator, a high-tech industry integrator and a technology finance integration service provider facing the future; striving to seek the organic integration and coordinated development of industrial real estate and industrial investment business, and making value discovery in the capital market (information source: https:// 2 The biomedical technology industry of the pharmaceutical enterprises settled by Zhangjiang hi tech is one of the main constructions of Zhangjiang hi tech (known as Zhangjiang pharmaceutical Valley) At present, it has formed a complete innovation chain from new drug exploration, drug screening, pharmacological evaluation, clinical research, pilot scale-up, registration and certification to mass production and listing It has gathered hundreds of enterprises, scientific research institutes and supporting service institutions in the field of life science at home and abroad, including a number of quite mature scientific research institutions, which have become the most professional cro institutions in the field of biological medicine at home and abroad High, the region with the most active R & D outsourcing business and the largest number of domestic innovative drug R & D At present, the national and Shanghai key research institutes include Shanghai Institute of medicine, Chinese Academy of Sciences, national new drug screening center, and national Shanghai new drug safety evaluation research center; well-known enterprises include Roche, Novartis, DuPont, Honeywell, Hutchison Whampoa, zaiding, Hualing, Shanghai Elis, and Heyu pharmaceutical, etc (information source: https:// 3 Output value of Zhangjiang biomedical industry Based on the introduction of the previous statistics of Pudong Development and Reform Commission (the first financial report), in 2016, there were 61 enterprises in Zhangjiang biopharmaceutical industry with an operating revenue of more than 100 million yuan, an increase of 8.9%; among them, the number of units in the biopharmaceutical industry was the largest, and the development was also fast, with an annual operating revenue of more than 8 billion yuan, an increase of 23.6%; and the growth rate of biomedical supporting service industry was the top among the sub industries, with an annual operating revenue of 8.9% Close to 6 billion yuan, with a growth rate of 91.6% In terms of intellectual property rights, in 2016, the number of patent applications and authorizations of Zhangjiang biomedical enterprises was 1221 and 630 respectively, up 25.4% and 2.3% year on year, including 232 international patent applications, 84 authorizations, up 14.2% and 71.4% respectively, and 225 trademark registrations, up 14.2% 4 Talent introduction Zhangjiang released: in 2017, the number of employees in Zhangjiang biomedical industry was 42000, a year-on-year increase of 4.4% There were 36500 people with college degree or above, including 8251 master's degree and 2751 doctor's degree; 162 experts at all levels, including 104 national experts, 44 provincial (city) level experts, and 14 district / county level experts; the number of scientific and technological activities was 13000, including 12000 R & D personnel, a year-on-year increase Length 17.9% The biomedical industry is also a big family of "Zhangjiang talents" and "thousand talents plan" In 2017, 9 people won the title of "Zhangjiang talents", including 3 outstanding talents and 6 outstanding talents; in 2017, the seventh batch of Shanghai "thousand talents plan" entrepreneurial talents project is to be selected, 6 of them are from Zhangjiang biomedical industry Zhangjiang pharmaceutical Valley is developing towards a talent system with high educational background, high level and high quality 5 Hundreds of new drug projects have been hatched According to the data query, there are nearly 200 innovative drug development varieties in the park, and the related varieties approved for marketing are as follows: tianenfu (recombinant human tumor necrosis factor for injection, only family Biology), furaquinotinib (VEGFR inhibitor, Hutchison Whampoa), treprizumab (shanghaijunshi), ruitongli (Shanghai Fudan Zhangjiang biological medicine), haimpofen (Shanghai Fudan Zhangjia biological medicine) Jiang biomedical, puyouke (Shanghai Tianshili pharmaceutical), Antofloxacin (Shanghai Pharmaceutical Research Institute), ankeri (Shanghai 3D Biotechnology Co., Ltd.), danorevir sodium (Shanghai Roche), xinlitan (Shanghai Elis), etc The varieties of NDA / BLA applied for were semidone (termination of pregnancy), recombinant human newlangreen (chronic heart failure), mannan oligosaccharide diacid (Alzheimer's disease), etc Phase III clinical varieties are trasatabine (leukemia), hlx-10 (PD-1), bergistine (breast cancer), contezolid (skin tissue infection), dorzagliatin (diabetes), entinstat (breast cancer), bpi-7711 (non-small cell lung cancer), vorolanib (tumor), epitinib (non-small cell lung cancer), voritinib (non-small cell lung cancer), suofenitini (non-small cell lung cancer)（ Neuroendocrine tumor, efentanil (non-small cell lung cancer), etc The total number of clinical varieties in phase II / I / application is more than 100 6 Brief introduction of representative new drugs of class 1 Fqtinib, developed by Hutchison Whampoa Pharmaceutical Co., Ltd., is a highly selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR); high efficiency, low toxicity and suitable for combination use are the excellent characteristics of fqtinib which are different from other approved small molecule VEGFR inhibitors; it is clinically used for the treatment of gastric cancer, advanced or metastatic colorectal cancer and non-small cell lung cancer; on September 5, 2018, fqtinib Quetinib has been approved to be listed by the drug examination department of China, and its indication is metastatic colorectal cancer In the near future, it is worth mentioning that in March 2019, furquitinib capsule again declared ind as a registered 2.4 drug Terripril mAb - Shanghai Junshi Trepril mAb, a humanized monoclonal antibody developed by Shanghai Junshi Biomedical Technology Co., Ltd., targets at programmed death receptor 1 (PD-1); in December 2018, the marketing application of trepril mAb injection was approved by nmpa for the treatment of unresectable or metastatic melanoma patients after the failure of previous systemic treatment, becoming the first in China PD-1 monoclonal antibody independently developed by China is listed in China Alisartan ester to Shanghai Ellis Alisartan ester, an angiotension II receptor antagonist, was developed by Shanghai ALIS Pharmaceutical Technology Co., Ltd in June 2007, the ind application of alisartan ester and tablet submitted by ALIS pharmaceutical was accepted by CFDA (1.1 chemicals); in October 2012, Shenzhen xinlitai Pharmaceutical Co., Ltd purchased alisartan ester from Shanghai ALIS Pharmaceutical Technology Co., Ltd Agent production technology: Jiangsu Ellis (Shanghai Ellis subsidiary) is responsible for the production of alisartan ester API, and xinlitai is responsible for the production and sales of its preparation alisartan ester tablets, with the trade name of xinlitan ® 7 Summary & exclaim that Zhangjiang is not only the dream place of Chinese pharmaceutical R & D personnel, but also the dream place of R & D personnel in many industries Today, with the rapid development of medical information, the outbound frequency of relevant pharmaceutical enterprises in Zhangjiang is no less than that of many first tier pharmaceutical enterprises in China, such as Hengrui, Zhengda Tianqing, etc Sometimes, the incubation ability of its varieties is not only amazing in speed, but also another way of thinking, which is quite different from the way of thinking of the old drug R & D enterprises and institutions Therefore, in general, the development of Zhangjiang biomedical industry has set an example for the development of domestic pharmaceutical parks and contributed to the incubation of domestic independent innovation of "class 1 new drugs"! Zhangjiang High Tech is definitely one of the important parks that every pharmaceutical R & D personnel need to pay attention to! Yaozhigu adopts the cooperative incubation mode of medical health big data application, and uses the four in one incubation mode of "data application, service entrepreneurship and innovation, project incubation, docking Park" to provide big data application, consulting service, academic conference, medical exhibition, talent service, entrepreneurship guidance, project roadshow, policy analysis, financing investment, public technology service platform, business for the park and enterprises Sales promotion and other service projects provide multi-functional one-stop service for innovation and Entrepreneurship of medical and health industry park Click "read the original" at the end of the article to enter the "pharmaceutical intelligence Valley", a service expert in the pharmaceutical health park "The view of this article only represents the author, not the position of pharmaceutical intelligence network Welcome to exchange and supplement in the message area If you need to reprint, please be sure to indicate the author and source of the article.